These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25999178)

  • 1. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.
    Oh DB
    BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of lysosomal storage diseases: recent patents and future strategies.
    Ortolano S; Viéitez I; Navarro C; Spuch C
    Recent Pat Endocr Metab Immune Drug Discov; 2014 Jan; 8(1):9-25. PubMed ID: 24433521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of Enzyme Drugs Derived from Transgenic Silkworms to Treat Lysosomal Diseases].
    Itoh K; Nishioka SI; Hidaka T; Tsuji D; Maita N
    Yakugaku Zasshi; 2018; 138(7):885-893. PubMed ID: 29962464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in development of transgenic silkworms overexpressing recombinant human proteins with therapeutic potential in silk glands.
    Itoh K; Kobayashi I; Nishioka S; Sezutsu H; Machii H; Tamura T
    Drug Discov Ther; 2016 Feb; 10(1):34-9. PubMed ID: 26971553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis.
    Bonten EJ; Wang D; Toy JN; Mann L; Mignardot A; Yogalingam G; D'Azzo A
    FASEB J; 2004 Jun; 18(9):971-3. PubMed ID: 15084520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy for lysosomal storage diseases.
    Lachmann RH
    Curr Opin Pediatr; 2011 Dec; 23(6):588-93. PubMed ID: 21946346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emptying the stores: lysosomal diseases and therapeutic strategies.
    Platt FM
    Nat Rev Drug Discov; 2018 Feb; 17(2):133-150. PubMed ID: 29147032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches for lysosomal storage diseases: a patent update.
    Urbanelli L; Sagini K; Polidoro M; Brozzi A; Magini A; Emiliani C
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-glycan structures and downstream mannose-phosphorylation of plant recombinant human alpha-L-iduronidase: toward development of enzyme replacement therapy for mucopolysaccharidosis I.
    Pierce OM; McNair GR; He X; Kajiura H; Fujiyama K; Kermode AR
    Plant Mol Biol; 2017 Dec; 95(6):593-606. PubMed ID: 29119347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.
    Solomon M; Muro S
    Adv Drug Deliv Rev; 2017 Sep; 118():109-134. PubMed ID: 28502768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies for enzyme replacement therapy for lysosomal storage diseases.
    Grubb JH; Vogler C; Sly WS
    Rejuvenation Res; 2010; 13(2-3):229-36. PubMed ID: 20345279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A polylysine-polyhistidine fusion peptide for lysosome-targeted protein delivery.
    Iwasaki T; Murakami N; Kawano T
    Biochem Biophys Res Commun; 2020 Dec; 533(4):905-912. PubMed ID: 33008588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies for the treatment of lysosomal storage diseases (review).
    Parenti G; Pignata C; Vajro P; Salerno M
    Int J Mol Med; 2013 Jan; 31(1):11-20. PubMed ID: 23165354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mannose-6-phosphate glycan for lysosomal targeting: various applications from enzyme replacement therapy to lysosome-targeting chimeras.
    Seo J; Oh DB
    Anim Cells Syst (Seoul); 2022; 26(3):84-91. PubMed ID: 35784393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Glycoengineered Enzyme with Multiple Mannose-6-Phosphates Is Internalized into Diseased Cells to Restore Its Activity in Lysosomes.
    Hyun JY; Kim S; Lee HS; Shin I
    Cell Chem Biol; 2018 Oct; 25(10):1255-1267.e8. PubMed ID: 30146240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.